Literature DB >> 17278949

Familial Mediterranean fever successfully treated with etanercept.

Adam Mor1, Michael H Pillinger, Mitsumasa Kishimoto, Aryeh M Abeles, Avi Livneh.   

Abstract

Colchicine is the only drug known to effectively prevent familial Mediterranean fever (FMF) attacks, as well as FMF-associated amyloidosis. Unfortunately, colchicine is neither always effective nor always well tolerated, leaving some patients and their physicians with inadequate weaponry to fight this hazardous disease. We present a patient with recurrent episodes of abdominal, scrotal, and joint attacks, who was diagnosed with FMF and advised to take colchicine. Diarrhea prevented optimal treatment with this drug and led to a trial of etanercept, with resolution of FMF manifestations. This case adds to a growing body of evidence suggesting that tumor necrosis factor (TNF) blockade may result in resolution and prevention of further FMF attacks.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278949     DOI: 10.1097/01.rhu.0000255772.25658.7c

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  17 in total

1.  Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra.

Authors:  Loes M Kuijk; Anita M A P Govers; Joost Frenkel; Willem J D Hofhuis
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 2.  Clinical immunology review series: An approach to the patient with a periodic fever syndrome.

Authors:  H J Lachmann
Journal:  Clin Exp Immunol       Date:  2011-07-07       Impact factor: 4.330

Review 3.  Autoinflammation: From monogenic syndromes to common skin diseases.

Authors:  Tien V Nguyen; Edward W Cowen; Kieron S Leslie
Journal:  J Am Acad Dermatol       Date:  2013-02-28       Impact factor: 11.527

4.  Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever.

Authors:  Nilüfer Alpay; Abdullah Sumnu; Yaşar Calışkan; Halil Yazıcı; Aydın Türkmen; Ahmet Gül
Journal:  Rheumatol Int       Date:  2010-04-13       Impact factor: 2.631

Review 5.  Chronic inflammation in FMF: markers, risk factors, outcomes and therapy.

Authors:  Ilan Ben-Zvi; Avi Livneh
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

6.  TNF/TNFR axis promotes pyrin inflammasome activation and distinctly modulates pyrin inflammasomopathy.

Authors:  Deepika Sharma; Ankit Malik; Clifford Guy; Peter Vogel; Thirumala-Devi Kanneganti
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 7.  Monogenic autoinflammatory diseases: concept and clinical manifestations.

Authors:  Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Clin Immunol       Date:  2013-04-09       Impact factor: 3.969

8.  Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy.

Authors:  Hatice Bodur; Umit Seçkin; Filiz Eser; Gülüşan Ergül; Selda Seçkin
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

9.  Sulphasalazine treatment in protracted familial Mediterranean fever arthritis.

Authors:  Sevcan A Bakkaloglu; Tekin Aksu; Berna Goker; Aysel Unlusoy; Harun Peru; Kibriya Fidan; Oguz Soylemezoglu; Enver Hasanoglu; Necla Buyan
Journal:  Eur J Pediatr       Date:  2008-11-26       Impact factor: 3.183

10.  Developments in the scientific and clinical understanding of autoinflammatory disorders.

Authors:  Helen J Lachmann; Philip N Hawkins
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.